Science

Emre Yekedüz: Adding 6 months of ADT to SBRT significantly improved clinical PFS compared to SBRT alone

lifelinecelltech.com

Mar 7, 2025, 03:20

Emre Yekedüz: Adding 6 months of ADT to SBRT significantly improved clinical PFS compared to SBRT alone

Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, shared an article by Giulia Marvaso, et al. on X:

“In patients with metachronous oligorecurrent hormone-sensitive Prostate Cancer, adding 6 months of ADT to SBRT significantly improved clinical progression-free survival compared to SBRT alone!

Phase 2, randomized trial.
105 patients, single-center (European Institute of Oncology, Milan).
SBRT (30 Gy/3 fx) ± 6 months ADT.”

ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.

Authors: Giulia Marvaso, et al.

Emre Yekedüz: Adding 6 months of ADT to SBRT significantly improved clinical PFS compared to SBRT alone

Ankara University cancer Emre Yekedüz European Institute of Oncology fight against cancer Giulia Marvaso Global fight against cancer MedOnc OncoDaily Oncology prostate cancer SBRT

Does Plastic Cause Cancer? Myths and Facts

TOPGEAR trial at ESTRO 2025: Preoperative Chemoradiotherapy for Resectable Gastric Cancer

Oncologist Near Me – Enrique Soto: A Leader in Geriatric Oncology and Global Cancer Care

Bianca Balti: The Supermodel’s Brave Battle with Ovarian Cancer

NCD Frontlines with Saunthari Somasundaram | A New OncoDaily Podcast – Coming Soon